Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions.
CONCLUSIONS: The advantages of bivalirudin are undoubtedly related to GPI use in the heparin arms. Bivalirudin-based regimens are more beneficial when compared with heparin and planned GPI use in terms of NACE and major bleedings; this was not observed when compared to heparin and provisional GPI use. Regardless of adjunctive GPI use, stent thrombosis episodes were significantly more common in bivalirudin-treated subjects. Therefore, the safety and economic issues may urge revision of this aspect of current clinical practice and guidelines.
PMID: 29350380 [PubMed - indexed for MEDLINE]
Source: Kardiologia Polska - Category: Cardiology Authors: Grajek S, Michalak M, GwizdaĆa A, Araszkiewicz A, Grygier M, Hiczkiewicz J, Lesiak M Tags: Kardiol Pol Source Type: research
More News: Angiomax | Bleeding | Cardiology | Cardiovascular | Clinical Trials | Heart | Heart Attack | Stroke | Study | Thrombosis